BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
2.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over $14 billion in revenue globally, reflecting surging demand for effective diabetes and obesity treatments (The Washington Post).
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
From Seoul's Global K-Wave to Web3 Leadership: Datavault AI and TBURN Chain Align K-Pop, Esports, and Korean Cultural Exports with Enterprise-Grade Data Asset Infrastructure and Tokenized Real World Assets18.2.2026 13:00:00 CET | Press release
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 18, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today announced the execution of a collaboration agreement with TBURN Chain Foundation ("TBURN"), a high-performance blockchain infrastructure platform. The agreement establishes a strategic framework to explore integration of Datavault's data asset tokenization, valuation, and Information Data Exchange® (IDE) technologies with TBURN's high-throughput blockchain network, which is designed to support enterprise-scale transaction processing and near-instant settlement. TBURN is engaged across global esports and entertainment ecosystems, including partnerships involving esports champion Faker and K-Pop acts such as BLACKPINK, providing potential pathways for authenticated digital engagement and data-driven monetization models. Originating f
The Numbers are Clear: Latest Iteration of Stagwell's News Advertising Study Shows Germans Love Their News18.2.2026 11:00:00 CET | Press release
Stagwell, Axel Springer, Teads and The Trade Desk partner on German News Advertising Study, drawing insights from over 11,000 respondents Study finds the proportion of ‘news junkies' in Germany is highest of all the surveyed markets BERLIN, GERMANY / ACCESS Newswire / February 18, 2026 / Stagwell, the global challenger network transforming marketing through AI, released the latest installment of its News Advertising Study in partnership with Axel Springer, Teads and The Trade Desk. The survey, fielded among 11,282 adults in Germany, builds on Stagwell's prior News Advertising studies conducted in Asia Pacific, Canada, the U.S. and UK. This regional study further reinforces it is safe for brands to advertise adjacent to quality news content agnostic of the topic. "The Future of News research for the German market illustrates how important it is for brands to advertise in quality news publications. Germany has a 10-percentage point higher share of news enthusiasts than other markets, and
Kraft Heinz, Braskem, and Tenaris to headline OMP Conference São Paulo 202617.2.2026 15:00:00 CET | Press release
Global industry leaders showcase real-world results and AI-driven supply chain planning innovations SÃO PAULO, BR / ACCESS Newswire / February 17, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, brings its REAL conference series to Latin America with a one-day event in São Paulo on April 16, 2026. The conference will bring together Fortune 500 leaders to share how they are transforming global operations through digital innovation. Under the theme "Real expertise. Real solutions. Real results," the conference focuses on the practical application of AI in complex supply chain environments. The agenda is anchored by three global powerhouses who will provide a "behind-the-scenes" look at their digital transformation journeys in partnership with OMP's Unison Planning™: Kraft Heinz, a global food and beverage company, will demonstrate how data-driven planning, AI-enabled optimization, and end-to-end visibility are building a more agile and sustainable value chai
Supported by U.S. Polo Assn., the 2026 U.S. Open Women's Polo Championship(R) Concludes with Victory Eastern Hay the Champion17.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL / ACCESS Newswire / February 17, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the 2026 U.S. Open Women's Polo Championship®, which concluded on February 15 at the USPA National Polo Center (NPC) in Wellington, Florida, on the iconic U.S. Polo Assn. Stadium Field. Widely regarded as the most prestigious women's polo tournament in the United States, the championship brought together the sport's top athletes for three weeks of elite competition at the heart of American polo.1. Victory Eastern Hay proudly displaying their trophy as winner of the 2026 U.S. Open Women's Polo Championship at the USPA National Polo Center 2. Victory Eastern Hay Team on horseback (#1 Rebecca Schmeits, #2 Aspen Tinto, #3 Hazel Jackson, #4 Milly Hine) at the 2026 U.S. Open Women's Polo Championship 3. La Dolfina Team presents a donation to their charity of choice, Polo Players Support Group, provided by U.S. Polo Assn., at th
Camino Intercepts High-Grade Copper with 83.5m at 0.94% Cu including 7.1m at 2.13% Cu at Los Chapitos, Peru17.2.2026 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company")is pleased to announce the exploration results from Phase 1 of the recent drilling campaign at its Los Chapitos copper project ("Los Chapitos" or the "Project") in Peru. This news release reports the results from eight drill holes completed along the Diva trend corridor, where drilling activities focused on several targets with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. Los Chapitos is Camino's second copper project with partner Nittetsu Mining Co, Ltd. ("Nittetsu"), who is completing a 35% earn-in interest in Los Chapitos after investing CAD $10 million and after the completion of Phase 2 of the current drilling campaign (see news release dated June 14, 2023). Camino is also advancing its Puquios Copper Project in Chile with Nittetsu Mining towards mine cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom